ABSTRACT
BACKGROUND AND OBJECTIVES: Viral and vascular disorders are considered to be a major cause of idiopathic sudden sensorineural hearing loss (ISSNHL). Lipoprostaglandin E₁ (lipo-PGE₁) has vasodilating activity and has been used to treat ISSNHL. The purpose of this study was to determine the specific therapeutic effects of lipo-PGE₁ and compare them to other treatment modalities for ISSNHL. SUBJECTS AND METHODS: The study group had 1,052 patients diagnosed with ISSNHL. All were treated with steroid, carbogen inhalation, stellate ganglion block (SGB), or PGE₁. The CP group (steroid, carbogen inhalation, and PGE1 injection; 288 patients) was treated with lipo-PGE₁ and carbogen inhalation, the CS group (steroid, carbogen inhalation, and stellate ganglion block; 232 patients) with steroid, carbogen inhalation, and SGB, the C group (steroid and carbogen inhalation; 284 patients) with steroid and carbogen, and the control group (steroid only; 248 patients) with steroid only. Patients in the groups receiving lipo-PGE₁ received a continuous infusion of 10 µL lipo-PGE₁. RESULTS: The overall recovery rate after treatment was 52.2%, and recovery rates by group were 67.7% in the CP group, 54.3% in the CS group, 52.1% in the C group, and 32.2% in the control group. Therefore, the therapeutic results in groups treated with lipo-PGE₁ were better than results in other groups. The difference was statistically significant. CONCLUSIONS: The study results suggested that the CP group received effective treatment modalities for ISSNHL. The combined therapy of lipo-PGE₁ with carbogen inhalation in patients with ISSNHL was more beneficial than other treatment modalities.
Subject(s)
Humans , Alprostadil , Hearing Loss, Sensorineural , Inhalation , Stellate Ganglion , Therapeutic UsesABSTRACT
Objective To explore the influence of Lipo PGE1 on endothelin (ET-1) and interleukin (IL-6) in exhaled breath condensate(EBC) of patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension(PH) and its clinical significance.Methods A total of 40 cases of patients with COPD and PH were randomly divided into thecontrol group and the treatment group,20 cases in each group.The control group was administered with the conventional treatments such as anti-infection,bronchodilator,antiasthma,expectorant and oxygen therapy;the treatment group was administered with Lipo PGE1 (10 μg/d,iv,for 10 days) besides the conventional treatments.ET-1 and IL-6 in EBC,pulmonary artery systolic pressure(PASP),arterial blood PaO2 and PaCO2,lung function FEV1/FVC,FEV1%pred in both groups were assayedbefore and after the treatment.Results There were no statistical difference between the two groups in the ET-1 and IL-6 in EBC,PASP,arterial blood PaO2 and PaCO2,FEV1/FVC,FEV1% pred before the treatment.After the treatment,the ET-1,IL-6 in EBC,PASP and arterial blood PaCO2 of the treatment group were lower than thoseof the control group (P<0.05);the arterial blood PaO2,FEV1/FVC,FEV1% pred of the treatment group were higher than those of the control group (P<0.05);The levels of ET-1 and IL-6 in EBC wereboth positivelycorrelated with PASP in the two groups.Conclusion Lipo PGE1 can reduce the levels of ET-1 and IL-6 in EBC of patients with COPD and PH.ET-1 and IL-6 may become a curative effect judgment index of COPD and PH,which has a certain clinical significance.
ABSTRACT
Objective To observe the clinical efficacy and safety of Shenxiong glucose injection and lipo PGE1 injection in treating the lower extremity arteriosclerotic occlusive disease (LEAOD).Methods 80 patients with LEAOD were randomly divided into control group and treatment group. Both groups were given conventional therapy, including reducing blood pressure, blood sugar, blood lipid and anti-infection therapy.Control group was additonally given intra-femoral arterial infusion with urokinase 150000 units plus 15mL 0.9% sodium chloride and 10 mg anisodamine alternately every other day, 5 days for one course, stopping 3 days after another course.Treatment group was treated with intravenous injection Lipo PGE1 injection plus 10 mL 0.9% sodium chloride and intravenous Shenxiong glucose injection per day for 14 days.Clinical efficacy, changes in clinical symptoms, whole blood viscosity, high sensitivity C-reactive protein(hs-CRP), fibrinogen, ankle-brachial index(ABI), the inner diameter of the dorsalis pedis and the peak systolic velocity( PSV) of dorsalis pedis were compared and analyzed pre and post-treatment.Adverse drug reactions were recorded during the treatment.ResuIts The efficiency for the patients in the treatment group (90.0%) was higher than that in control groups(72.5%) (P<0.05).The symptoms of numbness and cold limbs, whole blood viscosity, ABI, hs-CRP improved more significantly in the treatment group (P<0.05).No adverse event occurred in the treatment group and 2 patients in control group had mild dry mouth.ConcIusion Shenxiong glucose injection combined with lipo PGE1 injection for the treatment of LEAOD is effective and safe and should be introduced in clinical practice.
ABSTRACT
Objective To investigate the effects of Lipo-PGE1 on the expression of T-bet and Gata-3,and its potential mechanisms causing the shift of T cells from Th1 to Th2 on Acute lung injury(ALI)induced by Lipopolysaccharide(LPS)in mice.Methods Sixty male BALB-C mice were randomly divided into three groups(n =20 in each group):(1)control group,mice were treated with intravenous injection of NS in dose of 10 ml/kg,(2)LPS group,mice were exposed to LPS with dosage of 5 mg/kg(0.5 g/ml diluted in saline),and(3)LPS + PGE1 group,mice were treated with Lipo-PGE1 in dose of 15μg/kg.Sixhours after injection,the lungs were removed for observing the histopathological changes and determination of wet/dry lung weight(W/D)ratio.The levels of Th1 and Th2 were determined by flow cytometry,and the expressions of T-bet and Gata-3 mRNA were detected by using RT-PCR.One-way ANOVA was used for comparing differences between groups,and all data were presented in((x)± s).Results The histological changes of lung injury were lessened by PGEC ompared with the W/D ratio(5.74 ± 0.31)in LPS group,the one(4.92 ±0.27)in LPS +PGE1 group was lower significantly(P ＜0.01).The levels of Th1 and Th2 and their ratio Were higher in LPS +PGE1 group[(20.31 ±2.20)％,(10.50±0.80)％,(1.93±0.05)]than in LPS group[(16.65 ±1.70)％,(9.40 ±1.25)％,(1.73 ±0.03)](P＜0.01).Compared with control group,the expressions ofT-bet mRNA(1.183 ±0.495),and Gata-3 mRNA(0.693±0.285),and their ratio(1.713 ± 0.131)were lower(P ＜0.01); compared with LPS group,PGE1 significantly increased the expressions of T-bet mRNA(1.827 ± 0.705)and the ratio of T-bet/Gata-3 (2.502 ±0.352)(P ＜0.01),while didn(t)increased the expressions of Gata-3 mRNA(0.7191 ±0.186)significantly(P ＞ 0.05).Conclusions Lipo-PGE1 may up-regulate transcription factor T-bet which participates in the Th1 differentiation ratio,and then improve the inflammatorv svmntom.
ABSTRACT
PURPOSE: The survival of composite graft is dependent on three steps, (1) plasmatic imbibitions, (2) inosculation, and (3) neovascularization. Among the many trials to increase the survival rate of composite graft, prostaglandin E1 (PGE1) has beneficial effects on the microcirculatory level with vasodilating, antithrombotic, anti-inflammatory and neoangiogenic properties. Lipo-PGE1 which is lipid microspheres containing PGE1 had developed to compensate the systemic and local side effects of PGE1. This study was proposed to determine whether Lipo-PGE1 administration enhanced the survival of composite graft through neovascularization quantitatively in a rabbit ear model. METHODS: Fourteen New Zealand White Rabbits each weighing 3~4 kg were divided in two groups: (1) intravenous Lipo-PGE1 injection group and (2) control group. A 2 x 1 cm sized, full-thickness rectangular composite graft was harvested in each auricle. Then, the graft was reaaproximated in situ using a 5-0 nylon suture. For the experimental group, 3 microgram/kg/day of Lipo-PGE1 (5 microgram/mL) was administered intravenously through the marginal vein of the ear for 14 days. The control group was received no pharmacologic treatment. On the 14th postoperative day, composite graft of the ear was harvested and immunochemistry staining used Monoclonal mouse anti-CD 31 antibody was performed. Neoangiogenesis was quantified by counting the vessels that showed luminal structures surrounded by the brown color-stained epithelium and counted from 10 random high-power fields (400x) by independent blinded observer. Statistical analysis (Wilcoxon Signed Ranks test for nonparametric data) was performed using SPSS v12.0, with values of p<0.05 considered significant. RESULTS: The mean number of the microvessels was 15.48 +/- 8.65 in the experimental group and 9.82 +/- 7.25 in the control group (p=0.028). CONCLUSION: The use of Lipo-PGE1 facilitated the neoangiogenesis, resulted in the improvement of the survival rate of graft. On the basis of this results, we could support wider application of Lipo-PGE1 for more effective therapeutic angiogenesis and successful survival in various cases of composite graft in the human.
Subject(s)
Animals , Humans , Mice , Rabbits , Alprostadil , Ear , Epithelium , Immunochemistry , Microspheres , Microvessels , Nylons , Phenobarbital , Survival Rate , Sutures , Transplants , VeinsABSTRACT
PURPOSE: With the recent recognition of the importance of soft-tissue fillers, fat grafting has been assumed an increasingly important role as both an adjunctive and a primary procedure in aesthetic and reconstructive surgery. The main problem in achieving long-term soft-tissue augmentation is partial absorption of the injected fat and hence the need for overcorrection and re-injection. The purpose of this study is to improve the viability of the injected fat by the use of Lipo-PGE1. METHODS: Human adipose tissue, obtained by suction-assisted lipectomy, was re-injected into the subcutaneous layer in the scalp of ICR mice. Lipo-PGE1 (0.5 microgram/kg) was injected intravenously in experimental group for 7 days from the operation day and saline was injected in control group. There were 5 animals in each group. The animals were euthanized 4 weeks after the procedure. Graft weight and volume were measured and histologic evaluation was performed. RESULTS: Histologic analysis demonstrated significantly less cyst formation and less inflammatory reaction in the group treated with Lipo-PGE1. No significant difference was found between the groups regarding graft volume or the other histologic parameters investigated. Significant differences were demonstrated in microvascular density count. CONCLUSION: Less cyst formation, less inflammation, more angiogenesis indicating improved quality of the injected fat can be obtained by the addition of Lipo-PGE1. Further studies of various dosages of Lipo-PGE1 and their long-term effect are required before these encouraging results could be applied clinically.
Subject(s)
Animals , Humans , Mice , Absorption , Adipose Tissue , Alprostadil , Inflammation , Lipectomy , Mice, Inbred ICR , Scalp , Survival Rate , TransplantsABSTRACT
BACKGROUND AND OBJECTIVES: Sudden sensorineural hearing loss (SSNHL) is a disease, which occur rapidly within 3 days with unknown causes. Vascular and viral mechanisms are considered as the main cause, but an etiologcal background for vascular factors is more assumed. Carbogen inhalation and lipoprostaglandin E1, both of which have vasodilation effects, are used as treatment modalities in SSNHL. The purpose of this study was to recognize the effectiveness of lipo-PGE1 combined with carbogen inhalation, and to compare with other treatment modalities. SUBJECTS AND METHOD: The study group consisted of 224 patients (110 males, 114 females) diagnosed with SSNHL. We retrospectively reviewed patients who were admitted and treated from January 2001 to December 2005. All patients were treated with carbogen inhalation and drugs. Stellate ganglion block (SGB) and lipo-PGE1 were applied to patients selectively. Eighty-six patients (DCP group) were treated with lipo-PGE1, 49 patient (DCS group) with SGB, and 89 patients (DC group) without SGB. RESULTS: The overall recovery rates after the treatment were 59.8%. Therapeutic results of lipo-PGE1 group were better than those of other groups. CONCLUSION: Although various treatments for SSNHL have been proposed, lipo-PGE1 and carbogen inhalation were more effective and lipo-PGE1 is considered to be more helpful for SSNHL.
Subject(s)
Humans , Male , Alprostadil , Carbon Dioxide , Hearing Loss, Sensorineural , Hearing Loss, Sudden , Inhalation , Oxygen , Retrospective Studies , Stellate Ganglion , VasodilationABSTRACT
BACKGROUND: Lipo-prostaglandin E1 (Lipo-PGE1) has vasodilating and platelet aggregation inhibitory characteristics and it has been used as a treatment for patients with blood flow dysfunction disease. Based on the mechanisms of lumbar spinal stenosis, including veno congestion, neuro-ischemia and mechanical compression, we aimed to study whether intravenous Lipo-PGE1 injection has any therapeutic effect on hyperalgesia in a rat foraminal stenosis model. METHODS: In this study, twenty male Sprague-Dawley rats were divided into the control (n = 10) and Lipo-PGE(1)(n = 10) groups. A small stainless steel rod was inserted into the L5-6 intervertebral foramen to induce intervertebral foramen stenosis and chronic DRG compression. In the Lipo-PGE1 group, 0.15micron g/kg of Lipo-PGE(1) were injected intravenously via a tail vein for 10 days starting from the 3rd day after operation. Behavioral testing for mechanical and thermal hyperalgesia was performed for 3 weeks after the injections. RESULTS: From the 10th day after Lipo-PGE(1) injection, the rats in the experimental group showed significant recovery of their mechanical threshold, and this effect was maintained for 3 weeks. No significant differences of the thermal hyperalgesia were observed between the two groups. CONCLUSIONS: These findings suggest that intravenously injected Lipo-PGE1 may be effective for alleviating neuropathic pain, which isthe main symptom of spinal stenosis, by improving the blood flow dysfunction.
Subject(s)
Animals , Humans , Male , Rats , Alprostadil , Constriction, Pathologic , Diagnosis-Related Groups , Estrogens, Conjugated (USP) , Hyperalgesia , Neuralgia , Platelet Aggregation , Rats, Sprague-Dawley , Spinal Stenosis , Stainless Steel , VeinsABSTRACT
Objective To evaluate the clinical effect in the treatment of the young patients(≤45 years old) with acute myocardial infarction(AMI)underwent emergent percutaneous transluminal coronary angioplasty(PTCA) combined with Lipo-PGE_1.Methods 39 patients with AMI(paroxysm within 12 hours),were underwent emergent PTCA(coronary stem performed in some patients),including 18 cases which were treated combined with Lipo-PGE_1 in the mean time.And the clinical efficacy and the results of short-period follow-up were recorded.Results The in- farctive vasculars were re-open in 37 patients(23 cares were routinely placed translunrinal srents),and the successful rate was 94.9 %.Those who also used Lipo-PGE_1 were re-open in 17 patients.The successful rate was 94.4 %,their ST segments on EKG 30 minutes after operations reduced significantly than that of patients who did not use Lipo- PGE_1,their cardial functions were also improved significantly 24 hours after operations and no side effects on blood pressure and heart rate were observed.Conclusion The emergent PTCA combined with Lipo-PGE_1 for acute my- ocardial infarction can protect the cardial function and show a better early therapy effect.
ABSTRACT
Objective The aim of the study is to approach the clinical significance of the change of ST segments after di- rect percutaneous transcoronary angioplasty(PTCA) combined with Lipo-PGE_1 in treating Acute Myocardial Infarction (AMI).Methods The change of the ST segments on EKG of 76 patients with AMI are observed in 30 minutes after un- derwent direct PICA combined with Lipo-PGE_1,and the relations are analyzed that are prospectively to their therapy effect,the degree of injured cardiac muscle,the cardial functions,and the prognosis.Results The patients who treated with the PCTA combined with Lipo-PGE_1 ST segments on EKG 30 minutes after operations reduced significantly,cardiac muscle is injured lowly,their cardial functions are better.Conclusion The change of ST segments after direct percutane- ous transcoronary angioplasty (PTCA) combined with Lipo-PGE_1 in treating acute myocardial infarction is one of the guide line to estimate the perfnsion of cardiac muscle,and to estimate prognosis farther.
ABSTRACT
Objective To study the clinical effect of combined treatment of Lipo PGE1 and millimeter wave on diabetic peripheral neuropathy.Methods 98 patients with diabetic peripheral neuropathy(DPN)were randomly divided into the first treatment group with Lipo-PGE1,and the second treatment group combined with Lipo PGE1 and millimeter wave compared with the routin therapy group as control in order to observe the subjective symptom,tendon reflex and nerve conduction velocity,respectively.Results The total effective rates of the second treatment group was 91%,which was significantly higher than the control group(P
ABSTRACT
Objective To observe the effect of Lipo PGE1 and Mecobalamine and Ginkgo-dipyidamolun in the treatment of dia-betic peripheral neuropathy. Methods 60 Patients with diabetic peripheral neuropathy were divided randomly into two groups; the control group (30 cases) and the treatment group (30 cases). The patients of the treatment group were given with Lipo PGE1 100 ?g dissolved in 0.9% normal saline solution 100ml once a day intravenously, and given mecobalamine 500 ?g once a day intramuscular, and given Ginko-dipyidamolum injection 20ml dissolved in 0.9% normal saline solution 250ml once a day intravenously; and in the control group were only given with mecobalamine 500?g once a day intramuscular. Nerve conduction velocity (MNCV and SNCV) in two groups of patients was observed after 14 days treatment. Results After treatment for 14 days, the subjective symptoms and signs were significantly improved with a total effective rate of 86.7% in the treatment group versus 56.7% in the control group. Compared with the control group, the total effective rates of treatment group was significantly higher (P
ABSTRACT
The purpose of the present study was to examine a number of various times of Lipo-PGE1 administration in an attempt to determine the most effective time. In addition, this study examined the possible role of vascular endothelial growth factor(VEGF) on Lipo-PGE1 stimulation of a TRAM flap in the rat. Forty Sprague-Dawley rats were divided into 4 groups and a left inferior epigastric vessel pedicled TRAM flap, sized 5.0x3.5cm was created on the upper abdomen of each rat. Experimental groups included group 1(control): the flap was dissected and replaced, group 2(pharmacologic delay): Lipo-PGE1(0.5microgram) was given intraperitoneally for 5 days before elevation of flap daily, group 3(flap enhancement): Lipo- PGE1(0.5microgram) was given intraperitoneally for 5 days after flap elevation daily, group 4(pharmacologic delay and flap enhancement): Lipo-PGE1(0.5microgram) was given intraperitoneally for 5 days before elevation of flap then for 5 days after elevation of flap daily. On postoperative 5th day, we evaluated and compared the results of flap survival area, the number of blood vessel, and the VEGF expression using the western blot method. The results were as following: First, the mean percentage of the flap survival area of group II(63.9+/-12.6%), III(54.9+/-20.5%), IV(68.1+/- 18.2%) were higher than that of group I(28.7+/-15.2%) significantly(p<0.05). Second, the number of blood vessels were of group II(3.8+/-1.4), III(3.5+/-1.8), IV(4.0+/-1.5) were higher than that of group I(1.0+/-0.6) significantly(p<0.01). Third, the western blot method demonstrated a qualitatively greater amount of VEGF expression in the experimental groups. These results suggest that Lipo-PGE1 increased VEGF production and that Lipo-PGE1 may thereby enhance flap survival through VEGF production regardless of the time of Lipo-PGE1 administration.
Subject(s)
Animals , Rats , Abdomen , Alprostadil , Blood Vessels , Blotting, Western , Rats, Sprague-Dawley , Vascular Endothelial Growth Factor AABSTRACT
Objective To evaluate the effects of Lipo prostaglandin E1(Lipo-PGE1) on the lower limb blood vessel in diabetic patients.Methods The study was performed in 36 patients with diabetes related lower limb vascular disease.Before and after Lipo-PGE1 treatment for 28 days,vascular diameter and blood flow velocity of femoral artery,popliteal artery,posterior tibial artery and dorsal pedal artery were measured by Doppler ultrasonography examination.Results After the treatment with Lipo-PGE1,the vascular diameters of femoral artery,popliteal artery,posterior tibial artery and dorsal pedal artery were dilated;and there were significant differences in posterior tibial artery and dorsal pedal artery.After the treatment with Lipo-PGE1,blood flow velocity of femoral artery,popliteal artery,posterior tibial artery and dorsal pedal artery were increased,however,there were no significantly statistical differences.After the treatment with Lipo-PGE1,all the patients feel well.Painless walking distance and maximal walking distance of 18 patients with intermittent claudication were increased.Conclusion Lipo-PGE1 causes a significant improvement of diabetes related lower limb vascular disease.Furthermore,the results demonstrated the major effects on posterior tibial artery and dorsal pedal artery.Lipo-PGE1 can dilate the smaller artery,which is important and helpful for patients to improve symptoms and signs.
ABSTRACT
BACKGROUND/AIM: The lipo-PGE1, known for being more stable during pulmonary circulation and having more targeting effect, has been reported to inhibit ET-1 induced stellate cell contraction. We assessed the effect of lipo-PGE1 on the change of ET-1 concentration and the relationship between ET-1 concentration and the liver damage. METHODS: Mongrel dogs weighing about 25 kg were divided into a control (n=6) and a lipo-PGE1 (n=6) group. Partial liver allotransplantation was performed. In the lipo-PGE1 group, lipo-PGE1 was slowly infused through splenic venous cannulation during the donor liver harvesting procedure (50 microgram) and continuously infused (60 microgram/day) for 48 hours after reperfusion. The AST, ALP, LDH and ET-1 concentrations were monitored RESULTS: The AST and ALP levels of the lipo-PGE1 group were significantly lower than those of the control group both at 1 hour and 48 hours after reperfusion. The LDH level in the lipo-PGE1 group was lower at 1 hour and 48 hours after reperfusion. But there was no statistical difference between the two groups. The baseline ET-1 concentration of the lipo-PGE1 group was eight times higher than that of the control group. The ET-1 concentration was elevated gradually in the control group. There was no significant difference between the two groups at 48 hours. There was no correlation between ET-1 concentrations and AST, ALP, LDH levels. CONCLUSION: This study demonstrated the hepatoprotective effect of the lipo-PGE1 against ischemia-reperfusion injury in canine partial liver allotransplantation. However, the baseline ET-1 level was eight times higher in the lipo-PGE1 group than that of the control group in spite of the hepatoprotective effects of the lipo-PGE1.
Subject(s)
Animals , Dogs , Humans , Alprostadil , Catheterization , Endothelin-1 , Liver Transplantation , Liver , Pulmonary Circulation , Reperfusion , Reperfusion Injury , Tissue DonorsABSTRACT
PURPOSE: Hepatoprotective effect of prostaglandin E1 (PGE1) has been verified in numerous animal experiments but not so apparent in clinical trials. Although the reason for this discrepancy in clinical results is still unknown, one possible explanation is the instability of PGE1. In this study, the hepatoprotective effect of lipo-PGE1, which is known to be stable during pulmonary circulation and have more targeting effect, was investigated in canine partial liver allotansplantation. In order to reckon in the possible injury during harvest of partial liver, lipo-PGE1 was infused from the start of living graft harvest procedure. METHODS: Mongrel dogs weighing about 25 kg were divided into control (n=6) and lipo-PGE1 (n=6) group. Partial liver allotransplantation was performed. In lipo-PGE1 group, lipo-PGE1 was slowly infused through splenic venous cannulation during the donor liver harvesting procedure (50 mg) and continuously infused (60 mg/day) for 48 hrs after reperfusion. The aspartate aminotransferase (AST), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) were monitored. RESULTS: The AST and ALP levels of the lipo-PGE1 group were significantly lower than that of the control group at both 1 hour and 48 hours after reperfusion. The LDH level in lipo-PGE1 group was lower at 1 hour and 48 hours after reperfusion, but no significant differences were shown between two groups. CONCLUSION: This study demonstrated the hepatoprotective effect of the lipo-PGE1 against ischemia-reperfusion injury in canine partial liver allotransplantation.
Subject(s)
Animals , Dogs , Humans , Alkaline Phosphatase , Allografts , Alprostadil , Animal Experimentation , Aspartate Aminotransferases , Catheterization , L-Lactate Dehydrogenase , Liver Transplantation , Liver , Pulmonary Circulation , Reperfusion , Reperfusion Injury , Tissue Donors , TransplantsABSTRACT
OBJECTIVE:To investigate the therapeutic effect of Lipo-prostaglandin E 1 (Lipo PGE 1 )on chronic severe type B hepatitis by MELD(Model for end-stage live disease)prognosis analysis.METHODS:Of a total of115cases with chronic severe type B hepatitis,57were randomly assigned to receive a common combined therapy and58to receive a common combined therapy plus Lipo PGE 1 for4weeks,the MELD score and prognosis of diseases of the2groups were assessed.RE-SULTS:The MELD score in the treatment group(20.12?8.97)was lower than that of the control group(24.76?10.41)after4weeks’treatment(P